Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of Study M15-741 evaluating 24-hour continuous subcutaneous infusion of ABBV-951 in Parkinson's disease
2019-004235-23Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of foscarbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability (AEs and SAEs). Started May 2020; status: completed.
02
Drugs
foscarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2019-004235-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004235-23.